CAJ | 학술논문

目的：观察贝伐珠单抗联合伊立替康和卡培他滨方案治疗转移性结直肠癌的临床疗效和安全性。方法：回顾性分析天津医科大学肿瘤医院2008年1月至2011年12月收治的经病理学确诊的晚期结直肠癌53例，其中试验组27例，应用贝伐珠单抗联合伊立替康及卡培他滨治疗，对照组单纯应用伊立替康及卡培他滨治疗方案。比较两组临床疗效和安全性。结果：近期疗效比较，试验组与对照组的CR+PR（缓解率）差异无统计学意义(RR=24.15%，21.91%， P>0.05)，疾病控制率(CR+PR+SD)差异有统计学意义(86.30%，61.24%，P<0.05)。远期疗效比较，两组TTP分别为10.3个月、6.7个月，中位生存时间为18.2个月、13.6个月，差异有统计学意义(P<0.05)。两组不良反应没有差异，但试验组高血压发生率为27%，表现为舒张压升高，对症治疗后缓解。结论：贝伐珠单抗联合伊立替康及卡培他滨方案较单纯化疗可延长患者生存且疾病控制率好，不良反应无明显增加，可成为一线治疗方案。
목적：관찰패벌주단항연합이립체강화잡배타빈방안치료전이성결직장암적림상료효화안전성。방법：회고성분석천진의과대학종류의원2008년1월지2011년12월수치적경병이학학진적만기결직장암53례，기중시험조27례，응용패벌주단항연합이립체강급잡배타빈치료，대조조단순응용이립체강급잡배타빈치료방안。비교량조림상료효화안전성。결과：근기료효비교，시험조여대조조적CR+PR（완해솔）차이무통계학의의(RR=24.15%，21.91%， P>0.05)，질병공제솔(CR+PR+SD)차이유통계학의의(86.30%，61.24%，P<0.05)。원기료효비교，량조TTP분별위10.3개월、6.7개월，중위생존시간위18.2개월、13.6개월，차이유통계학의의(P<0.05)。량조불량반응몰유차이，단시험조고혈압발생솔위27%，표현위서장압승고，대증치료후완해。결론：패벌주단항연합이립체강급잡배타빈방안교단순화료가연장환자생존차질병공제솔호，불량반응무명현증가，가성위일선치료방안。
Objective:Observation of efifcacy and safety of bevacizumab plus capecitabine and irinotecan in the treatment of metastatic colorectal cancer.Methods:Retrospective analysis of 53 patients who were confirmed by pathology with metastatic colorectal cancer from January 2008 to December 2011. 27 patients received bevacizumab(7.5 mg·kg-1) plus capecitabine and irinotecan until disease progression or intolerable toxicity occurred. The other patients simply applied to the above chemotherapy. Results: In the recent therapeutic efifcacy, there was no statisticaly signiifcant response rate difference (CR + PR = 24.15%, 21.91%,P>0.05) between experimental group and control group, disease control rates (CR + PR + SD) difference was statisticaly signiifcant (86.30%, 61.24%,P < 0.05). In the long-term efifcacy comparison of two groups, TTP is 10.3 months vs. 6.7 months, respectively, the median survival time was 18.2 months vs. 13.6 months, the difference was statisticaly significant (P < 0.05). Adverse events(AEs) were no difference between two groups, but the incidence of hypertension was 27% in experimental group who showed the diastolic pressure and they were aleviated after medication. Conclusion:bevacizumab plus capecitabine and irinotecan is an effective and safe regimen as a ifrst-line treatment for patients with mCRC in China.